CELLECTAR BIOSCIENCES INC (CLRB) Fundamental Analysis & Valuation

NASDAQ:CLRB • US15117F8804

Current stock price

3.2 USD
-0.03 (-0.93%)
Last:

This CLRB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CLRB Profitability Analysis

1.1 Basic Checks

  • CLRB had negative earnings in the past year.
  • In the past year CLRB has reported a negative cash flow from operations.
  • CLRB had negative earnings in each of the past 5 years.
  • In the past 5 years CLRB always reported negative operating cash flow.
CLRB Yearly Net Income VS EBIT VS OCF VS FCFCLRB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of CLRB (-145.48%) is worse than 83.24% of its industry peers.
  • Looking at the Return On Equity, with a value of -219.69%, CLRB is doing worse than 69.56% of the companies in the same industry.
Industry RankSector Rank
ROA -145.48%
ROE -219.69%
ROIC N/A
ROA(3y)-224.89%
ROA(5y)-174.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLRB Yearly ROA, ROE, ROICCLRB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1K 2K 3K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CLRB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLRB Yearly Profit, Operating, Gross MarginsCLRB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. CLRB Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for CLRB has been increased compared to 1 year ago.
  • CLRB has more shares outstanding than it did 5 years ago.
  • CLRB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CLRB Yearly Shares OutstandingCLRB Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M
CLRB Yearly Total Debt VS Total AssetsCLRB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • CLRB has an Altman-Z score of -27.85. This is a bad value and indicates that CLRB is not financially healthy and even has some risk of bankruptcy.
  • CLRB's Altman-Z score of -27.85 is on the low side compared to the rest of the industry. CLRB is outperformed by 86.90% of its industry peers.
  • There is no outstanding debt for CLRB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -27.85
ROIC/WACCN/A
WACCN/A
CLRB Yearly LT Debt VS Equity VS FCFCLRB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M

2.3 Liquidity

  • A Current Ratio of 2.96 indicates that CLRB has no problem at all paying its short term obligations.
  • CLRB has a Current ratio of 2.96. This is in the lower half of the industry: CLRB underperforms 64.55% of its industry peers.
  • A Quick Ratio of 2.96 indicates that CLRB has no problem at all paying its short term obligations.
  • The Quick ratio of CLRB (2.96) is worse than 63.01% of its industry peers.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
CLRB Yearly Current Assets VS Current LiabilitesCLRB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. CLRB Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 72.11% over the past year.
EPS 1Y (TTM)72.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.33%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CLRB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.09% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y25.46%
EPS Next 2Y22.27%
EPS Next 3Y19.58%
EPS Next 5Y18.09%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CLRB Yearly Revenue VS EstimatesCLRB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 50M 100M 150M 200M 250M
CLRB Yearly EPS VS EstimatesCLRB Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -1K -2K -3K

More info and screens

Find the best growth stocksShow best growing peers

0

4. CLRB Valuation Analysis

4.1 Price/Earnings Ratio

  • CLRB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLRB. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLRB Price Earnings VS Forward Price EarningsCLRB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLRB Per share dataCLRB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6 -8 -10

4.3 Compensation for Growth

  • CLRB's earnings are expected to grow with 19.58% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.27%
EPS Next 3Y19.58%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CLRB Dividend Analysis

5.1 Amount

  • No dividends for CLRB!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CLRB Fundamentals: All Metrics, Ratios and Statistics

CELLECTAR BIOSCIENCES INC

NASDAQ:CLRB (3/13/2026, 8:17:34 PM)

3.2

-0.03 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-04
Earnings (Next)05-11
Inst Owners8.21%
Inst Owner Change17.11%
Ins Owners0.58%
Ins Owner Change0%
Market Cap13.57M
Revenue(TTM)N/A
Net Income(TTM)-21.79M
Analysts80
Price Target47.94 (1398.12%)
Short Float %2.87%
Short Ratio1.5
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.08%
Min EPS beat(2)44.85%
Max EPS beat(2)45.31%
EPS beat(4)4
Avg EPS beat(4)30.23%
Min EPS beat(4)14.78%
Max EPS beat(4)45.31%
EPS beat(8)6
Avg EPS beat(8)32.7%
EPS beat(12)7
Avg EPS beat(12)16.95%
EPS beat(16)9
Avg EPS beat(16)14.76%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)6.15%
EPS NY rev (1m)0%
EPS NY rev (3m)3.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.37
P/tB 1.37
EV/EBITDA N/A
EPS(TTM)-10.29
EYN/A
EPS(NY)-7.67
Fwd EYN/A
FCF(TTM)-5.45
FCFYN/A
OCF(TTM)-5.45
OCFYN/A
SpS0
BVpS2.34
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -145.48%
ROE -219.69%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224.89%
ROA(5y)-174.4%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 2.76%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.96
Quick Ratio 2.96
Altman-Z -27.85
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)162.52%
Cap/Depr(5y)146.84%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)72.11%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.33%
EPS Next Y25.46%
EPS Next 2Y22.27%
EPS Next 3Y19.58%
EPS Next 5Y18.09%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y55.56%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.51%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.42%
OCF growth 3YN/A
OCF growth 5YN/A

CELLECTAR BIOSCIENCES INC / CLRB Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for CELLECTAR BIOSCIENCES INC?

ChartMill assigns a fundamental rating of 2 / 10 to CLRB.


What is the valuation status of CELLECTAR BIOSCIENCES INC (CLRB) stock?

ChartMill assigns a valuation rating of 0 / 10 to CELLECTAR BIOSCIENCES INC (CLRB). This can be considered as Overvalued.


Can you provide the profitability details for CELLECTAR BIOSCIENCES INC?

CELLECTAR BIOSCIENCES INC (CLRB) has a profitability rating of 0 / 10.


Can you provide the financial health for CLRB stock?

The financial health rating of CELLECTAR BIOSCIENCES INC (CLRB) is 5 / 10.